查詢結果分析
相關文獻
- Fulminant Hepatic Failure between Cyclic Adjuvant Chemotherapy in an Ovarian Immature Teratoma Patient with Hepatitis B:Report of One Case
- 非小細胞肺癌術前輔助性化學治療的經驗
- Carcinosarcoma of the Ovary: A Case Report
- Amnestic Disorder due to an Immature Ovarian Teratoma--Paraneoplastic Limbic Encephalitis
- Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: An 2002 Update
- 輔助性化學治療
- Adjuvant Chemotherapy for Stage III Colorectal Cancer in Elderly Patients
- 第二期大腸癌病人開刀後存活分析:著眼於化學治療--單一醫學中心的經驗
- Laparoscopic Total Mesorectal Excision in Locally Advanced Rectal Cancer
- 新型輔助性化學治療(Neoadjuvant Chemotherapy)可以提供第四期大腸直腸癌合併無法切除之轉移病灶的病人較好的預後
頁籤選單縮合
題 名 | Fulminant Hepatic Failure between Cyclic Adjuvant Chemotherapy in an Ovarian Immature Teratoma Patient with Hepatitis B:Report of One Case=B型肝炎帶原之卵巢癌病人接受化學治療發生猛爆性肝衰竭:病例報告 |
---|---|
作 者 | 魏天山; 楊育正; 蘇聰賢; | 書刊名 | 中華民國婦產科醫學會會刊雜誌 |
卷 期 | 36:4 1997.12[民86.12] |
頁 次 | 頁157-162 |
分類號 | 417.25 |
關鍵詞 | 輔助性化學治療; 乙型肝炎之猛爆性活化; 卵巢不成熟畸胎瘤; Adjuvant chemotherapy; Fulminant reactivation of hepatitis B; Ovarian immature teratoma; |
語 文 | 英文(English) |
中文摘要 | 背景:輔助性化學治療已被廣泛地使用在婦科癌症上;然而化學治療卻可能引起許 多器官系統的副作用。在這�塈畯抭孎i一例乙型肝炎表面抗原陽性的病人,因為卵巢不成熟 畸胎瘤做化學治療,卻引起猛爆性肝炎而致命。 病例報告:一位婦女因左卵巢腫瘤而在其他醫院接受左卵巢輸卵管切除手術。病理報告 是中度分化的卵巢不成熟畸胎瘤,因此她被轉介到我們醫院做化學治療。她接受了"BEP"混合 藥物的化學治療,預計三個療程每三個禮拜一次,從1995年八月十二日開始。在做完第二個 療程後兩個禮拜,她的肝功能呈現了下降的情況,而且很快地急速惡化成猛爆性肝炎;檢驗報 告顯示可能是乙型肝炎的猛爆性活化。雖然我們盡可能搶救,但是在兩個月後,病人還是因 為肝腎症候群而死亡。 結論:在進行化學治療之前,所有乙型肝炎好發地區的病人都應接受乙型肝炎表面抗原 的檢驗。對於那些乙型肝炎病毒有precore突變者或是治療中發生乙型肝炎病毒去氧核醣核 酸活性增加的高危險群病人,我們必須特別加以注意。 |
英文摘要 | Background: Adjuvant chemotherapy is used worldwide in gynecological cancers, however, cytotoxic chemotherapy can cause many toxic side effects. Here, we present a patient with positive hepatitis B surface antigen (HBsAg) that died of fulminant hepatitis between cyclic chemotherapy for ovarian immature teratoma. Case report: A woman was diagnosed with a large ovarian tumor in a local hospital, where she underwent a left salpingo-oophorectomy. Unfortunately, the pathologic report revealed a stage 1A grade 2 ovarian immature teratoma, and she was referred to our hospital for further therapy. Here, she received chemotherapy of the "BEP" regimen starting from August 12, 1995. After the second course of chemotherapy for 2 weeks, her liver function became impaired and soon deteriorated in the following days. The laboratory findings revealed fulminant reactivation of hepatitis B virus (HBV). Two months later, she died of hepatorenal syndrome. Conclusion: The HBsAg serum markers should be tested for all patients who are going to receive cytotoxic chemotherapy, especially in HBV endemic regions. Chemotherapy should be closely monitored for high risk patients with HBV precore mutation or increased HBV-DNA activity. |
本系統中英文摘要資訊取自各篇刊載內容。